PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26216931-10	2015	A time-dependent P-selectin expression was observed in prasugrel but not in ticagrelor-treated patients (prasugrel early 11.9 +- 9.4% vs. late 26.3 +- 19.0%, P = 0.031, ticagrelor early 9.6 +- 4.9% vs. late 13.5 +- 6.6%, P = 0.127).	Ticagrelor	169-179	selectin P	Homo sapiens	17-27	
32062795-7	2020	In contrast, Pam3CSK4-induced platelet surface expression of P-selectin and activated GPIIb/IIIa were significantly lower in ticagrelor-treated patients (both p <= 0.005).	Ticagrelor	125-135	selectin P	Homo sapiens	61-71	
32062795-8	2020	Moreover, SFLLRN-induced platelet surface expression of P-selectin and activated GPIIb/IIIa were significantly less pronounced in patients on ticagrelor therapy compared to prasugrel-treated patients (both p < 0.03).	Ticagrelor	142-152	selectin P	Homo sapiens	56-66	
28503981-5	2018	We found that aspirin plus prasugrel or aspirin plus ticagrelor inhibited platelet responses to multiple agonists and reduced P-selectin expression.	Ticagrelor	53-63	selectin P	Homo sapiens	126-136	
32564571-9	2021	However, P-selectin was lower in the ticagrelor group compared with clopidogrel group.	Ticagrelor	37-47	selectin P	Homo sapiens	9-19	
30745807-7	2019	Compared to clopidogrel-treated patients, CD42+/CD62P+ PMVs counts were 3-4-fold lower in subjects receiving ticagrelor (p=0.001) or prasugrel (p&lt;0.05), while CD42+ PMVs were significantly reduced on ticagrelor (by about 6-fold, p&lt;0.001), but not prasugrel (p=0.3).	Ticagrelor	109-119	selectin P	Homo sapiens	48-53	
30745807-10	2019	Conclusions: Higher antiplatelet potency of prasugrel and ticagrelor versus clopidogrel is associated with decreased plasma CD42+/CD62P+ PMVs numbers.	Ticagrelor	58-68	selectin P	Homo sapiens	130-135